NR1H4 and prostate cancer: Several compounds have been repurposed to block EphA2 action as EphA2 antagonists, including Farnesoid X Receptor (FXR), GW4064, cilofexor, nidufexor, tropifexor, turofexorate isopropyl, and vonafexor, which demonstrated good preclinical results in tumor models, including prostate cancer [80].